Related Experiment Video
Updated: Aug 19, 2026
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Is troponin I gene therapy effective for osteosarcoma treatment? Study on a human-like orthotopic rat model
A Dutour1, H Rabinovich-Chable, C Kaletta
1Department of Medical Biochemistry School of Medicine, University of Limoges, 2 rue Dr Raymond Marcland, 87042 Limoges, France.
Background:
An anti-angiogenesis strategy has been widely recognized as a viable approach to fight cancer and more and more anti-angiogenic factors are continually being identified. Among them, the muscular isoform of Troponin I (TnI) has been described as being a powerful anti-angiogenic agent in vitro as well as in vivo. We investigated the therapeutic efficacy of TnI gene therapy in a human-like orthotopic rat osteosarcoma model.
Materials And Methods:
In this tumor model, we evaluated whether the administration of the secreted TnI coding sequence complexed to cationic liposomes (named TnITag cDNA/lCLP) could induce a delay in tumor growth and reduce tumor vasculature.
Results:
Although TnI specifically inhibited endothelial cell growth in vitro, we were not able to demonstrate any therapeutic efficacy of TnI in the transplantable osteosarcoma model.
Conclusion:
This lack of efficacy probably resulted from the rapid degradation of recombinant TnI by matrix metalloproteinases, especially MMP2, which are present in large amounts in tumors.
Insights
Troponin I (TnI) gene therapy showed no efficacy in an osteosarcoma rat model. Rapid degradation by matrix metalloproteinases (MMPs) likely caused this lack of therapeutic effect in vivo.
Area of Science:
- Oncology
- Gene Therapy
- Cancer Research
Background:
- Anti-angiogenesis is a key cancer treatment strategy.
- Muscular Troponin I (TnI) exhibits potent in vitro and in vivo anti-angiogenic properties.
- TnI's potential as an anti-cancer therapeutic warrants investigation.
Purpose of the Study:
- To evaluate the therapeutic efficacy of TnI gene therapy in a rat osteosarcoma model.
- To determine if TnI administration could inhibit tumor growth and reduce tumor vasculature.
Main Methods:
- An orthotopic osteosarcoma rat model was utilized.
- Secreted TnI coding sequence complexed to cationic liposomes (TnITag cDNA/lCLP) was administered.
- Tumor growth and vasculature were assessed post-treatment.
Main Results:
- TnI demonstrated specific inhibition of endothelial cell growth in vitro.
- No significant therapeutic efficacy of TnI was observed in the osteosarcoma model.
- Tumor growth and vasculature were not effectively reduced by TnI gene therapy.
Conclusions:
- The lack of therapeutic efficacy is likely due to rapid degradation of recombinant TnI.
- Matrix metalloproteinases (MMPs), particularly MMP2, abundant in tumors, are suspected to degrade TnI.
- Further strategies are needed to protect TnI from degradation for effective in vivo anti-cancer therapy.
